PD-1在4NQO诱导的小鼠口腔黏膜鳞癌中表达变化

Abstract

Abstract: Objective　 To identify the changes and potential roles of immune checkpoint PD-1 in oral squamous cell carcinoma (OSCC) microenvironment. Methods　 The oral squamous cell carcinoma model of C57 mice was induced and established by potable water containing 4-nitroquinoline-1-oxide (4NQO). Lesion location of the oral squamous cell carcinoma of the mice model was detected and analyzed by histopathology. Real-time PCR and flow cytometry were used to detect the expression level of PD-1 gene and protein. Results　 OSCC model was successfully induced by exposing to 4NQO after 28 weeks. Histopathological evaluation showed that oral mucosal squamous cell carcinoma occurred in mice. Real-time PCR and flow cytometry showed that PD-1 gene and protein expression in CD4+ T cell was significantly up-regulated in tongue mucosal tumor tissues and spleen. Conclusion　 PD-1 shows significant up-regulation in mice OSCC and is possibly related to the development of OSCC.

Key words: mice oral mucosa, 4-nitroquinoline-1-oxide, oral squamous cell carcinoma, PD-1

CLC Number:

R839.85

References 21

[1]	CHI A C, DAY T A, NEVILLE B W. Oral cavity and oropharyngeal squamous cell carcinoma--an update[J]. CA Cancer J Clin, 2015, 65(5):401-21.
[2]	SIEGEL R L, MILLER K D, JEMAL A. Cancer statistics, 2018[J]. CA Cancer J Clin, 2018, 68(1):7-30.
[3]	OLIVEIRA-COSTA J P, DE CARVALHO A F, DA SILVEIRA DA G G, et al. Gene expression patterns through oral squamous cell carcinoma development: PD-L1 expression in primary tumor and circulating tumor cells[J]. Oncotarget, 2015, 6(25):20902-20.
[4]	WEI S C, ANANG N A S, SHARMA R, et al. Combination anti-CTLA-4 plus anti-PD-1 checkpoint blockade utilizes cellular mechanisms partially distinct from monotherapies[J]. Proc Natl Acad Sci U S A, 2019.
[5]	CHEN L, HAN X. Anti-PD-1/PD-L1 therapy of human cancer: past, present, and future[J]. J Clin Invest, 2015, 125(9):3384-91.
[6]	TOPALIAN S L, HODI F S, BRAHMER J R, et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer[J]. N Engl J Med, 2012, 366(26):2443-54.
[7]	SEIWERT T Y, BURTNESS B, MEHRA R, et al. Safety and clinical activity of pembrolizumab for treatment of recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-012): an open-label, multicentre, phase 1b trial[J]. Lancet Oncol, 2016, 17(7):956-965.
[8]	SCULLY C, BAGAN J V. Recent advances in oral oncology 2008; squamous cell carcinoma imaging, treatment, prognostication and treatment outcomes[J]. Oral Oncol, 2009, 45(6):e25-30.
[9]	GILDENER-LEAPMAN N, FERRIS R L, BAUMAN J E. Promising systemic immunotherapies in head and neck squamous cell carcinoma[J]. Oral Oncol, 2013, 49(12):1089-96.
[10]	TAKAHASHI H, YANAMOTO S, YAMADA S, et al. Effects of postoperative chemotherapy and radiotherapy on patients with squamous cell carcinoma of the oral cavity and multiple regional lymph node metastases[J]. Int J Oral Maxillofac Surg, 2014, 43(6):680-5.
[11]	HUGHES P E, CAENEPEEL S, WU L C. Targeted Therapy and Checkpoint Immunotherapy Combinations for the Treatment of Cancer[J]. Trends Immunol, 2016, 37(7):462-476.
[12]	ROTTE A. Combination of CTLA-4 and PD-1 blockers for treatment of cancer[J]. J Exp Clin Cancer Res, 2019, 38(1):255.
[13]	LEE H T, LEE S H, HEO Y S. Molecular Interactions of Antibody Drugs Targeting PD-1, PD-L1, and CTLA-4 in Immuno-Oncology[J]. Molecules, 2019, 24(6).
[14]	FORSCHNER A, BATTKE F, HADASCHIK D, et al. Tumor mutation burden and circulating tumor DNA in combined CTLA-4 and PD-1 antibody therapy in metastatic melanoma - results of a prospective biomarker study[J]. J Immunother Cancer, 2019, 7(1):180.
[15]	MIRANDA S R, NOGUTI J, CARVALHO J G, et al. Oxidative DNA damage is a preliminary step during rat tongue carcinogenesis induced by 4-nitroquinoline 1-oxide[J]. J Mol Histol, 2011, 42(2):181-6.
[16]	KANOJIA D, VAIDYA M M. 4-nitroquinoline-1-oxide induced experimental oral carcinogenesis[J]. Oral Oncol, 2006, 42(7):655-67.
[17]	吴祥冰. TGM3和MAL基因在口腔鳞癌发生发展中作用[D]. 上海交通大学, 2014.
[18]	FERRIS R L, BLUMENSCHEIN G, JR., FAYETTE J, et al. Nivolumab for Recurrent Squamous-Cell Carcinoma of the Head and Neck[J]. N Engl J Med, 2016, 375(19):1856-1867.
[19]	MATTOX A K, LEE J, WESTRA W H, et al. PD-1 Expression in Head and Neck Squamous Cell Carcinomas Derives Primarily from Functionally Anergic CD4(+) TILs in the Presence of PD-L1(+) TAMs[J]. Cancer Res, 2017, 77(22):6365-6374.
[20]	LUI V W, HEDBERG M L, LI H, et al. Frequent mutation of the PI3K pathway in head and neck cancer defines predictive biomarkers[J]. Cancer Discov, 2013, 3(7):761-9.
[21]	IGLESIAS-BARTOLOME R, MARTIN D, GUTKIND J S. Exploiting the head and neck cancer oncogenome: widespread PI3K-mTOR pathway alterations and novel molecular targets[J]. Cancer Discov, 2013, 3(7):722-5.

Alteration of PD-1 expression in mice oral squamous cell carcinoma induced by 4-nitroquinoline-1-oxide

Knowledge

Abstract

Cite this article

share this article

References 21

Related Articles 15

Recommended Articles

Metrics

Comments

[1]	. Mechanism research of YAP1-FOS promoting cell proliferation, migration and EMT in oral squamous cell carcinoma [J]. , 2019, 39(7): 581-586.
[2]	. Advances in the study of factors related to the occurrence and development of oral squamous cell carcinoma mediated by PI3K/AKT pathway [J]. , 2019, 39(6): 552-556.
[3]	. Inhibitory effect of danshensu on oral squamous cell carcinoma CAL-27 cells in vitro [J]. , 2019, 39(2): 113-116.
[4]	. A clinicopathological study of the prognosis and metastasis of MMP-14 in oral cancer patients [J]. , 2018, 38(8): 685-689.
[5]	. DNA quantitative analysis of oral squamous cell carcinoma and its clinical significance [J]. , 2018, 38(7): 616-619.
[6]	. Influence of nobelitin on the proliferation，migration and invasion of oral squamous cell carcinoma Cal-27 cells [J]. , 2018, 38(6): 481-484.
[7]	. Non-invasive Human Papilloma Virus Detection of Oral leukoplakia and Squamous Cell Carcinomas [J]. , 2018, 38(6): 528-532.
[8]	. Expression regulation of microRNA and oral squamous cell carcinoma [J]. , 2018, 38(5): 476-480.
[9]	. Relationship between E-cadherin and MMP-1 expressions and prognosis in oral squamous cell carcinoma [J]. , 2018, 38(1): 39-43.
[10]	. Effect of staurosporine on cell proliferation and apoptosis in oral squamous cell carcinoma cell line CAL27 [J]. , 2017, 37(7): 598-602.
[11]	chen xin. Current situation of oral squamous cell carcinoma [J]. , 2017, 37(5): 462-465.
[12]	. The expressions of Slug and E-cadherin in oral squamous cell carcinoma [J]. , 2017, 37(3): 214-218.
[13]	. The prognostic significance of peripheral blood eosinophilia in oral squamous cell carcinoma after surgery [J]. , 2016, 36(6): 546-549.
[14]	. MicroRNA27b inhibits cell proliferation of oral squamous cell carcinoma through targeting FZD7 [J]. , 2016, 36(3): 200-205.
[15]	. A primary study of differentially expressed proteins in the serums of healthy people and patients with oral squamous cell carcinoma [J]. , 2016, 36(2): 105-108.